Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713310 | 0.90 | HPGDS (0.62) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL13577909 | 0.88 | NAAA (0.65) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL14082177 | 0.86 | HPGDS (0.59) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL4910794 | 0.84 | HPGDS (0.57) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL6718174 | 0.84 | NPC1 (0.57) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL14082178 | 0.83 | HPGDS (0.61) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL14006248 | 0.82 | CHRNA7 (0.72) | HPGDSHTR2CDRD3HTR1ADRD2 | |
| SCHEMBL6714939 | 0.81 | NPC1 (0.57) | HPGDSKMT2AMEN1HTR2CDRD3 | |
| SCHEMBL2975968 | 0.81 | DRD2 (0.68) | DRD3DRD2POLBDRD4 | |
| SCHEMBL4911901 | 0.81 | CHRNA7 (0.74) | HPGDSHTR2CDRD3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | HPGDS 3191/4885KMT2A 2403/4885MEN1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.